|
1
|
Jemal A, Bray F, Center MM, et al: Global
cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
|
|
2
|
Lam WK, White NW and Chan-Yeung MM: Lung
cancer epidemiology and risk factors in Asia and Africa. Int J
Tuberc Lung Dis. 8:1045–1057. 2004.PubMed/NCBI
|
|
3
|
Kobayashi N, Kostka G, Garbe JH, et al: A
comparative analysis of the fibulin protein family. Biochemical
characterization, binding interactions, and tissue localization. J
Biol Chem. 282:11805–11816. 2007. View Article : Google Scholar
|
|
4
|
Timpl R, Sasaki T, Kostka G and Ghu ML:
Fibulins: a versatile family of extracellular matrix proteins. Nat
Rev Mol Cell Biol. 4:479–489. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pupa SM, Giuffré S, Castiglioni F, et al:
Regulation of breast cancer response to chemotherapy by fibulin-1.
Cancer Res. 67:4271–4277. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yi CH, Smith DJ, West WW and Hollingsworth
MA: Loss of fibulin-2 expression is associated with breast cancer
progression. Am J Pathol. 170:1535–1545. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Albig AR and Schiemann WP: Fibulin-5
antagonizes vascular endothelial growth factor (VEGF) signaling and
angiogenic sprouting by endothelial cells. DNA Cell Biol.
23:367–379. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang Y and Marmorstein LY: Focus on
molecules: fibulin-3 (EFEMP1). Exp Eye Res. 90:374–375. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sadr-Nabavi A, Ramser J, Volkmann J, et
al: Decreased expression of angiogenesis antagonist EFEMP1 in
sporadic breast cancer is caused by aberrant promoter methylation
and points to an impact of EFEMP1 as molecular biomarker. Int J
Cancer. 124:1727–1735. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yue W, Dacic S, Sun Q, et al: Frequent
inactivation of RAMP2, EFEMP1 and Dutt1 in lung cancer by promoter
hypermethylation. Clin Cancer Res. 13:4336–4344. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nomoto S, Kanda M, Okamura Y, et al:
Epidermal growth factor-containing fibulin-like extracellular
matrix protein 1, EFEMP1, a novel tumor-suppressor gene
detected in hepatocellular carcinoma using double combination array
analysis. Ann Surg Oncol. 17:923–932. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lecka-Czernik B, Lumpkin CK Jr and
Goldstein S: An overexpressed gene transcript in senescent and
quiescent human fibroblasts encoding a novel protein in the
epidermal growth factor-like repeat family stimulates DNA
synthesis. Mol Cell Biol. 15:120–128. 1995.PubMed/NCBI
|
|
13
|
Hata K, Dhar DK, Watanabe Y, et al:
Expression of metastin and a G-protein-coupled receptor (AXOR12) in
epithelial ovarian cancer. Eur J Cancer. 43:1452–1459. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Albig AR, Neil JR and Schiemann WP:
Fibulins 3 and 5 antagonize tumor angiogenesis in vivo. Cancer Res.
66:2621–2629. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hu B, Thirtamara-Rajamani KK, Sim H and
Viapiano MS: Fibulin-3 is uniquely upregulated in malignant gliomas
and promotes tumor cell motility and invasion. Mol Cancer Res.
7:1756–1770. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Seeliger H, Camaj P, Ischenko I, et al:
EFEMP1 expression promotes in vivo tumor growth in human pancreatic
adenocarcinoma. Mol Cancer Res. 7:189–198. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang R, Zhang YW and Chen LB: Aberrant
promoter methylation of FBLN-3 gene and clinicopathological
significance in non-small cell lung carcinoma. Lung Cancer.
69:239–244. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim EJ, Lee SY, Woo MK, et al: Fibulin-3
promoter methylation alters the invasive behavior of non-small cell
lung cancer cell lines via MMP-7 and MMP-2 regulation. Int J Oncol.
40:402–408. 2012.PubMed/NCBI
|
|
19
|
Tong JD, Jiao NL, Wang YX, Zhang YW and
Han F: Downregulation of fibulin-3 gene by promoter methylation in
colorectal cancer predicts adverse prognosis. Neoplasma.
58:441–448. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cristofanilli M, Hayes DF, Budd GT, et al:
Circulating tumor cells: a novel prognostic factor for newly
diagnosed metastatic breast cancer. J Clin Oncol. 23:1420–1430.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Osta WA, Chen Y, Mikhitarian K, et al:
EpCAM is overexpressed in breast cancer and is a potential target
for breast cancer gene therapy. Cancer Res. 64:5818–5824. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Allard WJ, Matera J, Miller MC, et al:
Tumor cells circulate in the peripheral blood of all major
carcinomas but not in healthy subjects or patients with
nonmalignant diseases. Clin Cancer Res. 10:6897–6904. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pass HI, Levin SM, Harbut MR, et al:
Fibulin-3 as a blood and effusion biomarker for pleural
mesothelioma. N Engl J Med. 367:1417–1427. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hsu HH, Liu CJ, Shen CY, et al: p38α MAPK
mediates 17β-estradiol inhibition of MMP-2 and −9 expression and
cell migration in human lovo colon cancer cells. J Cell Physiol.
227:3648–3660. 2012.
|
|
25
|
Kumar B, Koul S, Petersen J, et al: p38
mitogen-activated protein kinase-driven MAPKAPK2 regulates invasion
of bladder cancer by modulation of MMP-2 and MMP-9 activity. Cancer
Res. 70:832–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
